|
Obecabtagene autoleucel Clinical Trials
3 actively recruiting trials across 3 locations
No change since June 2026
Also known as: Obe-cel
Pipeline
Phase 2: 3
Top Sponsors
- Memorial Sloan Kettering Cancer Center1
- M.D. Anderson Cancer Center1
- Autolus Limited1
Stanford, California1 trial
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Stanford University (Data Collection AND Specimen Analysis)
Phase 2
Syracuse, New York1 trial
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
State University of New York Upstate Medical Center (SUNY)
Phase 2
Houston, Texas1 trial
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
The University of Texas M. D. Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.